The re-emergence of hallucinogenic research.
Matthew J Begola, Jonathan S Dowben
Perspectives In Psychiatric Care October 2018 DOI: 10.1111/ppc.12263 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Intervention | Hallucinogens |
| Topics | MDMA PTSD |
| Keywords | Clinical trials Hallucinogens |
| Key points | Argues that because PTSD can at times be intractable to treatment, clinicians and researchers continue to explore different options, including a renewed interest in hallucinogens for treating the disorder. |
Abstract
Due to the intractability, at times, in the treatment of PTSD, clinicians and researchers continue to explore different options for treatment. This article discusses the renewed interest in hallucinogens for such treatment.
Citations in the library
Cites 4
- Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction Current Drug Abuse Reviews January 9, 2015
- Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? Journal of Psychopharmacology February 9, 2015
- Classic hallucinogens in the treatment of addictions. Progress in Neuro-Psychopharmacology and Biological Psychiatry January 4, 2016
- MDMA is certainly damaging after 25 years of empirical research: a reply and refutation of Doblin et al. (2014). Human Psychopharmacology: Clinical and Experimental March 2014